Nanobody-based depletion or reprogramming of protumoral tumor-associated macrophages for the enhancenment of therapy response.

Project Details


Clinical and experimental studies delineate protumorigenic roles for immune cell subsets, in particular tumor-associated macrophages or TAM. Hence, it seems plausible to target these cells and eliminate or reprogram their function, but at present the role of distinct TAM subsets in vivo are largely non-existing. Very recent evidence, from our lab and others, identified the Macrophage Mannose Receptor (MMR, CD206) as a marker for strongly protumorigenic TAM. Indeed, MMR TAM were reported to contribute to diminished therapy responsiveness and tumor relapse following anti-angiogenic or vascular disrupting therapies and chemotherapy in preclinical tumor models. Interestingly, our previous work provided the first evidence that Nanobodies (Nbs), generated against mouse MMR, efficiently penetrate solid mouse tumors and specifically recognize MMR TAM, providing a solid basis for Nb-mediated TAM targeting.
The ultimate deliverable of this study should be an anti-MMR Nb-conjugate lead compound for future clinical use as tool for the elimination of tumor-supporting macrophages, resulting in a higher efficiency of combined conventional therapies.
Effective start/end date15/11/1514/11/19


  • Nanobodies